Connecting with Investors at the Maxim Growth Summit
OAK RIDGE, TN — Daxor Corporation (Nasdaq: DXR), renowned for its advancements in blood volume measurement technology, is excited to announce that Michael Feldschuh, the President and CEO, will engage with institutional investors at the upcoming Maxim Growth Summit. This exclusive event takes place at the Hard Rock Hotel in New York City and is set for two days filled with insightful discussions and opportunities.
Exclusive Access to One-on-One Investor Meetings
At the Summit, attendees will have the unique opportunity to schedule one-on-one meetings with Mr. Feldschuh, gaining insight into Daxor's innovative solutions and future strategies. Alongside these personal interactions, Feldschuh will be collaborating with senior analysts from Maxim Group throughout the event.
What to Expect at the Summit
The Maxim Growth Summit is designed to showcase a carefully curated selection of promising healthcare companies. Various keynote speakers will share their expertise, including prominent figures like Larry Kudlow and Christopher Ruddy. The event’s emphasis is on high-quality networking and investment opportunities, making it a significant gathering for small-cap investors.
About Daxor Corporation
Daxor Corporation is tackling a pressing issue in healthcare—the lack of efficient blood volume measurement. This challenge often leads to inadequate patient care, longer hospital stays, and increased rates of readmission for serious medical conditions such as heart failure. With over 50 years of expertise, Daxor has developed its FDA-approved Blood Volume Analysis (BVA) diagnostic technology. This pioneering tool offers real-time, precise blood volume measurements, helping clinicians tailor treatments to individual patient needs, which ultimately enhances outcomes and reduces costs associated with care.
Innovative Technology and Expansion
Daxor operates out of a state-of-the-art, 20,000-square-foot manufacturing facility and is ISO certified, positioning the company to enhance market reach and operational efficiency. As the healthcare industry continues to evolve, Daxor remains committed to innovation and quality in their product offerings, ensuring that they meet the growing demands of healthcare providers and patients alike.
Investor Relations
For potential investors looking to explore opportunities with Daxor, please reach out to our Investor Relations team. Bret Shapiro, COO and Head of Capital Markets at COREIR, is your primary contact for any inquiries or to arrange meetings during the summit. Interested parties can contact him at (561)-479-8566 or via email.
Frequently Asked Questions
What is the Maxim Growth Summit?
The Maxim Growth Summit is an exclusive event that gathers institutional investors and a select group of promising healthcare companies, including Daxor Corporation.
Who is Michael Feldschuh?
Michael Feldschuh is the President and CEO of Daxor Corporation, leading the company’s strategies and initiatives in blood volume measurement technology.
What technology does Daxor specialize in?
Daxor specializes in blood volume measurement technology, providing precise data through its FDA-cleared Blood Volume Analysis diagnostic tool.
How can investors contact Daxor's Investor Relations?
Investors can contact Bret Shapiro at COREIR via phone at (561)-479-8566 or via email for inquiries and meeting arrangements.
What are the benefits of Daxor's technology?
Daxor's technology offers real-time insights for clinicians, improving patient outcomes and enhancing efficiencies in medical treatment protocols.
